AR118361A2 - Sales monoclorhidrato de un inhibidor de histona deacetilasa - Google Patents
Sales monoclorhidrato de un inhibidor de histona deacetilasaInfo
- Publication number
- AR118361A2 AR118361A2 ARP200100716A ARP200100716A AR118361A2 AR 118361 A2 AR118361 A2 AR 118361A2 AR P200100716 A ARP200100716 A AR P200100716A AR P200100716 A ARP200100716 A AR P200100716A AR 118361 A2 AR118361 A2 AR 118361A2
- Authority
- AR
- Argentina
- Prior art keywords
- forms
- salts
- inhibitor
- monochlorhydrate
- mono
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente provee formas cristalinas de sales mono-HCl y una sal hidrato mono-HCl de JNJ-26481585, un inhibidor de histona deacetilasa. La presente se refiere, además, a procesos para la producción de dichas formas, a intermediarios utilizados en dichos procesos, a composiciones farmacéuticas que comprenden dichas formas, y a la utilización de dichas formas en un tratamiento médico, por ejemplo, como medicamento para inhibir afecciones proliferativas, tales como, por ejemplo, cáncer y leucemia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07108176 | 2007-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118361A2 true AR118361A2 (es) | 2021-09-29 |
Family
ID=38659779
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102021A AR066550A1 (es) | 2007-05-14 | 2008-05-13 | Sales monoclorhidrato de un inhibidor de histona deacetilasa |
| ARP200100716A AR118361A2 (es) | 2007-05-14 | 2020-03-13 | Sales monoclorhidrato de un inhibidor de histona deacetilasa |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102021A AR066550A1 (es) | 2007-05-14 | 2008-05-13 | Sales monoclorhidrato de un inhibidor de histona deacetilasa |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US20100130523A1 (es) |
| EP (1) | EP2155677B1 (es) |
| JP (1) | JP2010526851A (es) |
| KR (1) | KR101540679B1 (es) |
| CN (1) | CN101679256B (es) |
| AP (1) | AP2717A (es) |
| AR (2) | AR066550A1 (es) |
| AU (1) | AU2008250047B2 (es) |
| BR (1) | BRPI0811859B8 (es) |
| CA (1) | CA2683195C (es) |
| CL (1) | CL2008001390A1 (es) |
| CO (1) | CO6140031A2 (es) |
| CR (1) | CR11163A (es) |
| CY (1) | CY1115837T1 (es) |
| DK (1) | DK2155677T3 (es) |
| EA (1) | EA018326B1 (es) |
| EC (1) | ECSP099729A (es) |
| ES (1) | ES2525456T3 (es) |
| HK (1) | HK1140479A1 (es) |
| HR (1) | HRP20141180T1 (es) |
| IL (1) | IL202042A0 (es) |
| JO (1) | JO2959B1 (es) |
| MX (1) | MX2009012332A (es) |
| NZ (1) | NZ599674A (es) |
| PA (1) | PA8780301A1 (es) |
| PL (1) | PL2155677T3 (es) |
| PT (1) | PT2155677E (es) |
| RS (1) | RS53672B1 (es) |
| SG (1) | SG182986A1 (es) |
| SI (1) | SI2155677T1 (es) |
| TW (1) | TWI414294B (es) |
| UA (1) | UA100510C2 (es) |
| WO (1) | WO2008138918A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009015917A2 (en) | 2007-05-14 | 2009-02-05 | F. Hoffmann-La Roche Ag | Dihydroquinone and dihydronaphthridine inhibitors of jnk |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5924990B2 (ja) * | 1979-11-21 | 1984-06-13 | 協和醗酵工業株式会社 | 新規なピペリジン誘導体 |
| DE69620445T2 (de) | 1995-12-08 | 2002-12-12 | Janssen Pharmaceutica Nv | (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren |
| BRPI0513878A (pt) * | 2004-07-26 | 2008-05-20 | Applied Research Systems | derivados de n-hidroxiamida e uso dos mesmos |
| NZ552865A (en) * | 2004-07-28 | 2009-09-25 | Janssen Pharmaceutica Nv | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
-
2008
- 2008-05-06 JO JO2008202A patent/JO2959B1/en active
- 2008-05-12 CL CL2008001390A patent/CL2008001390A1/es unknown
- 2008-05-12 PA PA20088780301A patent/PA8780301A1/es unknown
- 2008-05-13 SI SI200831339T patent/SI2155677T1/sl unknown
- 2008-05-13 ES ES08750252.2T patent/ES2525456T3/es active Active
- 2008-05-13 JP JP2010507895A patent/JP2010526851A/ja active Pending
- 2008-05-13 TW TW097117494A patent/TWI414294B/zh active
- 2008-05-13 KR KR1020097021648A patent/KR101540679B1/ko active IP Right Grant
- 2008-05-13 MX MX2009012332A patent/MX2009012332A/es active IP Right Grant
- 2008-05-13 PL PL08750252T patent/PL2155677T3/pl unknown
- 2008-05-13 AR ARP080102021A patent/AR066550A1/es active IP Right Grant
- 2008-05-13 AU AU2008250047A patent/AU2008250047B2/en active Active
- 2008-05-13 NZ NZ599674A patent/NZ599674A/xx unknown
- 2008-05-13 SG SG2012048781A patent/SG182986A1/en unknown
- 2008-05-13 EA EA200971031A patent/EA018326B1/ru unknown
- 2008-05-13 EP EP08750252.2A patent/EP2155677B1/en active Active
- 2008-05-13 WO PCT/EP2008/055804 patent/WO2008138918A1/en active Application Filing
- 2008-05-13 US US12/598,743 patent/US20100130523A1/en not_active Abandoned
- 2008-05-13 DK DK08750252.2T patent/DK2155677T3/en active
- 2008-05-13 PT PT87502522T patent/PT2155677E/pt unknown
- 2008-05-13 BR BRPI0811859A patent/BRPI0811859B8/pt active IP Right Grant
- 2008-05-13 AP AP2009005039A patent/AP2717A/xx active
- 2008-05-13 CA CA2683195A patent/CA2683195C/en active Active
- 2008-05-13 RS RS20140662A patent/RS53672B1/en unknown
- 2008-05-13 UA UAA200910196A patent/UA100510C2/ru unknown
- 2008-05-13 CN CN2008800163514A patent/CN101679256B/zh active Active
-
2009
- 2009-09-30 CO CO09107340A patent/CO6140031A2/es unknown
- 2009-11-11 EC EC2009009729A patent/ECSP099729A/es unknown
- 2009-11-11 IL IL202042A patent/IL202042A0/en active IP Right Grant
- 2009-12-14 CR CR11163A patent/CR11163A/es not_active Application Discontinuation
-
2010
- 2010-07-15 HK HK10106880.8A patent/HK1140479A1/xx unknown
-
2012
- 2012-05-30 US US13/483,678 patent/US8759519B2/en active Active
-
2014
- 2014-12-05 HR HRP20141180AT patent/HRP20141180T1/hr unknown
- 2014-12-17 CY CY20141101062T patent/CY1115837T1/el unknown
-
2020
- 2020-03-13 AR ARP200100716A patent/AR118361A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY33547A (es) | COMPUESTOS QUÍMICOS Bcl-2 y Bcl-XL | |
| PH12017501306A1 (en) | Inhibitors of histone demethylases | |
| CL2016002970A1 (es) | Sales de adición de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo. | |
| CR20140036A (es) | Compuesto inhibidor de la señalización de la trayectoria notch | |
| CL2015002698A1 (es) | Nuevos compuestos y composiciones para la inhibicion de fasn | |
| UY33539A (es) | Compuestos químicos alk | |
| CU20120169A7 (es) | Compuestos pirimidinílicos como inhibidores de la cinasa atr | |
| EA201391390A1 (ru) | Циклопропиламины в качестве ингибиторов lsd | |
| AR087451A1 (es) | Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes | |
| NI200900184A (es) | Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer. | |
| UY32096A (es) | Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones | |
| ECSP11011307A (es) | Comprimidos para terapia de combinacion | |
| UA109290C2 (uk) | Спільні кристали і солі інгібіторів ccr3 | |
| UY33305A (es) | Compuestos heterocíclicos inhibidores de DGAT1 | |
| AR118361A2 (es) | Sales monoclorhidrato de un inhibidor de histona deacetilasa | |
| NI200900185A (es) | Sales monoclohidrato de un inhibidor de histona deacetilasa | |
| GT201500189A (es) | Inhibidores de autotaxina | |
| CO6400187A2 (es) | Tabletas para terapia de combinación | |
| UA110834C2 (uk) | Сполука-інгібітор сигнального шляху notch | |
| SA515360233B1 (ar) | مثبطات إنزيمات هستون ديميثيلاز | |
| NI201200162A (es) | Inhibidores de pirazolil quinoxalina cinasa |